NCT04682041View on ClinicalTrials.gov

Evaluating the Impact of EnteraGam In People With COVID-19

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

December 20, 2021

Study Completion Date

February 21, 2022

Conditions
Covid19
Interventions
DIETARY_SUPPLEMENT

Bovine Plasma-Derived Immunoglobulin Concentrate

EnteraGam® 10.0 g, containing 5.0 g of serum-derived bovine immunoglobulin/protein isolate (SBI) BID (every 12 hours) for 2 weeks.

OTHER

Standard of care

Standard of care PSMAR protocol for COVID-19 patients.

Trial Locations (1)

08003

Hospital del Mar, Barcelona

Sponsors

Lead Sponsor

Entera Health, Inc
All Listed Sponsors
collaborator

Lemus Buhils, SL

UNKNOWN

collaborator

Clinical Research Unit, IMIM (Hospital del Mar Medical Research Institute)

UNKNOWN

lead

Entera Health, Inc

INDUSTRY

NCT04682041 - Evaluating the Impact of EnteraGam In People With COVID-19 | Biotech Hunter | Biotech Hunter